Tempus AI vs Amgen
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI precision medicine company. NASDAQ: TEM. 2025 revenue $1.27B (+83% YoY). World's largest clinical/molecular data library. Founded 2015, Chicago. 2026 guidance ~$1.59B.
About
Tempus AI is an AI-powered precision medicine company founded in 2015 by Eric Lefkofsky in Chicago, Illinois. The company has built the world's largest library of clinical and molecular data, comprising over 40 million research records including 1.5 million with matched clinical-genomic data. Tempus provides precision medicine services across oncology, cardiology, radiology, and depression through Genomics, Data and Services, and AI Applications product lines.
Amgen (AMGN) reported $33.4B revenue in FY2024, up 19% YoY (post-Horizon acquisition). Top-5 global biotech. 10+ blockbuster drugs. ~24,000 employees. HQ: Thousand Oaks, CA. Market cap ~$130B.
About
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologics and brought landmark medicines including Epogen, Neupogen, and Enbrel to market. The company reported revenues of $33.4B in FY2024, up 19% year-over-year, boosted by the transformational $28B acquisition of Horizon Therapeutics in October 2023.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.